Viking Therapeutics has delivered a very large 5 year return, yet its current checks lean expensive, which raises questions about how much of the obesity drug opportunity is already reflected in the stock price
- Viking Therapeutics has returned about 6x over 5 years, which puts extra focus on whether recent gains leave limited room for disappointment.
- The launch of the Phase 1 trial for obesity candidate VK3019 can support expectations for a broader weight loss pipeline. At the same time, clinical and regulatory setbacks across this portfolio remain a central risk to any valuation built on future treatments.
- The company screens as expensive on Simply Wall St’s broader checks, with 0 of 6 valuation metrics suggesting it is a clear bargain.
The issue now is whether Viking Therapeutics’ recent share price strength is justified by its long term earnings and cash flow potential, or if expectations have moved too far ahead of the fundamentals
Find out why Viking Therapeutics’ 39.5% return over the last year is lagging behind its peers
Advertisement
Does Viking Therapeutics Look Pricey on Book Value?
For a loss making biotech like Viking Therapeutics, the P/B ratio is often used as a quick way to see how heavily the market values its research pipeline and balance sheet
Viking Therapeutics trades at a P/B of about 9.7x, compared with an industry average of roughly 2.8x and a peer group average near 5.6x. As a result, the stock sits on a sizeable premium to both broader biotechs and closer comparables. This gap indicates that investors are currently paying a higher price for Viking Therapeutics’ obesity and metabolic programs, including the recently highlighted VK2735 and VK3019 candidates, even though the company is still working through clinical and regulatory milestones.
Despite the recent focus on new obesity drug trials, the current P/B multiple places Viking Therapeutics at a valuation level that is high relative to sector norms
On this P/B yardstick, Viking Therapeutics stock appears clearly overvalued compared with its biotech peers
See what the numbers say about this price — find out in our valuation breakdown
The Viking Therapeutics Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives pick up where this valuation puzzle for Viking Therapeutics leaves off by making clear which future growth, margin and earnings assumptions would need to hold for the stock to be worth materially more or less than today’s price. They sit on Simply Wall St’s Community page as scenario-style views. Rather than focusing on a single multiple or output, each one lays out the assumptions behind its fair value so you can weigh them against actual results as they emerge
One of the top community narratives on Viking Therapeutics: 66% undervalued
“The oral VK2735 program, supported by Phase II data with double digit weight loss percentages and plans to move into Phase III, gives Viking a second high value product path that may diversify future revenue sources and create operating leverage if both oral and injectable share the same active molecule…”
Read one of the top narratives on Viking Therapeutics
Do you think there’s more to the story for Viking Therapeutics? Head over to our Community to see what others are saying!
The Bottom Line
Viking Therapeutics currently screens as overvalued on traditional market multiples, with a P/B ratio well above both the broader biotech group and closer peers. That premium rests on confidence that its obesity and metabolic pipeline, including VK2735 and VK3019, can eventually justify a richer valuation than other loss making biotechs. For you, the key question is whether the current price already bakes in much of that potential, or if the science, trial outcomes and regulatory progress can still surprise positively enough to support today’s elevated expectations.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free
• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks
Try a Demo Portfolio for Free
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
About NasdaqCM:VKTX
Viking Therapeutics
A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders
See The Free Research Report
Flawless balance sheet with very low risk
See The Free Research Report
Market Insights
Q-Day: The risk the market forgot to repriceRichard Bowman
Finding dividends that actually lastMitchell Lawler
Watt’s left in the overcrowded power trade?Richard Bowman
Advertisement
Weekly Picks
LO
Lou_Baseneseon Giftify·3 months ago
Giftify ($GIFT): A Small-Cap Incentives Platform with More ScaleThan Its Valuation Suggests
Fair Value:US$2.562.2% undervalued
36followersusers have followed this narrative
·1commentusers have commented on this narrative
·8likesusers have liked this narrative
HA
HarishPKon lululemon athletica·28 days ago
Quantifying the Transition: Why Lululemon’s Moat Remains Intact
Fair Value:US$161.828.9% undervalued
10followersusers have followed this narrative
·0commentsusers have commented on this narrative
·8likesusers have liked this narrative
TR
tripledubon Alphabet·about 1 month ago
Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late
Fair Value:US$23059.6% overvalued
41followersusers have followed this narrative
·1commentusers have commented on this narrative
·10likesusers have liked this narrative
JO
John_Ericon Veeva Systems·5 days ago
AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability
Fair Value:US$32039.9% undervalued
14followersusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
RecentlyUpdated Narratives
DA
davidlsanderon Nevgold·about 1 hour ago
The U.S. Government Is Desperate for This Metal. This Tiny Miner Has It — Its Closest Peer Is Already Worth Double
Fair Value:US$2.1929.2% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
GE
Germaineon Kucingko Berhad·about 7 hours ago
Kucingko Berhad: Fundamentals Show Early Recovery as Creative Content Expansion Gains Traction
Fair Value:RM 0.012733.3% overvalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
BL
Blaggeton BP Silver·about 10 hours ago
“valer un Potosí” GOOGLE IT. Now you’re should be kinda locked in. Educate yourself, Read the rest
Fair Value:CA$685.7% undervalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
Popular Narratives
IN
Investingwillyon Mastercard·20 days ago
Mastercard: The Best Dividend Stock You’re Ignoring
Fair Value:US$75029.1% undervalued
84followersusers have followed this narrative
·1commentusers have commented on this narrative
·9likesusers have liked this narrative
HA
HarishPKon Adobe·26 days ago
Adobe: A Probabilistic Case for Undervaluation
Fair Value:US$319.9630.8% undervalued
64followersusers have followed this narrative
·9commentsusers have commented on this narrative
·19likesusers have liked this narrative
BL
BlackGoaton Cerebras Systems·16 days ago
The Wafer Giant Threatening NVIDIA’s GPU Hegemony
Fair Value:US$415.5457.5% undervalued
59followersusers have followed this narrative
·3commentsusers have commented on this narrative
·10likesusers have liked this narrative
